BIONOMICS LTD. news, videos and press releases
For more news please use our advanced search feature.
BIONOMICS LTD. - More news...
BIONOMICS LTD. - More news...
- Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq
- Bionomics Announces Supreme Court of New South Wales Approves Bionomics’ Re-Domiciliation
- Results of Scheme Meeting
- Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence
- Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting
- Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States
- Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement
- Bionomics to Present at the 2024 CNS Summit
- Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program
- Bionomics to Present at the ThinkEquity Conference
- Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
- Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision
- Bionomics Limited announces intention to re-domicile to the United States
- Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder
- Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024
- Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder
- Bionomics Limited Announces Private Placement of up to $70.0 Million
- Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
- Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
- Bionomics to Present at the 2024 BIO CEO & Investor Conference
- Bionomics Provides a Review of 2023 and of 2024 Plans
- Bionomics to Present at Biotech Showcase™ 2024
- Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting
- Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder
- Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
- Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD
- Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210
- Quarterly Activities and Cashflow Report
- Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX)
